title: Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.
abstract: MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3)-glucan. We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp. MK-3118 demonstrated enhanced efficacy for most C. albicans and C. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC50s).
authors: Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
authors: Cristina
authors: C
authors: Jiménez-Ortigosa
authors: Padmaja
authors: P
authors: Paderu
authors: Mary R
authors: MR
authors: Motyl
authors: David S
authors: DS
authors: Perlin
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology*; D001230:Aspergillus / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D002175:Candida / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D025141:Drug Resistance, Fungal; D054714:Echinocandins / Q000494:pharmacology; D006027:Glycosides / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D014315:Triterpenes / Q000494:pharmacology*; D047071:beta-Glucans / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D006027:Glycosides; D014315:Triterpenes; D047071:beta-Glucans; C033363:beta-1,3-glucan; C569338:ibrexafungerp